Clinical bottom line
Current evidence does not support the routine use of low-dose naltrexone (LDN) for the management of chronic obstructive pulmonary disease (COPD) in primary care. While LDN has been explored in various chronic inflammatory and pain conditions, robust clinical data demonstrating its efficacy or safety in COPD are lacking. Established COPD management remains focused on inhaler therapies, smoking cessation, and non-pharmacological interventions as outlined in current guidelines. Any consideration of LDN for COPD should be regarded as experimental and warrant careful clinical evaluation within research settings.
What the evidence shows
COPD is a complex, progressive respiratory disease characterized by airflow limitation and chronic inflammation of the airways (Chavez et al., 2009). Standard management in primary care emphasizes inhaled bronchodilators, corticosteroids, smoking cessation, and pulmonary rehabilitation (Yawn et al., 2012; Yawn et al., 2021). These approaches target symptom control, exacerbation prevention, and quality of life improvement.
Low-dose naltrexone, an opioid receptor antagonist at doses typically ranging from 1 to 5 mg daily, has been hypothesized to modulate immune function and reduce inflammation in several chronic conditions. However, the literature vetted for COPD does not include well-designed clinical trials or systematic reviews evaluating LDN’s efficacy or safety in this population. The existing COPD management literature (MacIntyre et al., 2001; Braman et al., 2010) does not mention LDN as a therapeutic option, reflecting its absence from current evidence-based guidelines.
Non-pharmacological symptom management strategies, including patient-directed music listening during mechanical ventilation and pulmonary rehabilitation, have demonstrated benefit in COPD symptom control (Heiderscheit et al., 2021). These remain the cornerstone of adjunctive care alongside pharmacotherapy.
Caveats and uncertainty
The absence of high-quality clinical trial data on LDN in COPD means any potential benefits or harms remain unknown. The immunomodulatory effects of LDN observed in other diseases are mechanistically intriguing but unproven in the context of COPD’s complex inflammatory milieu. COPD patients often have multiple comorbidities and polypharmacy, raising concerns about off-label use without safety data.
Furthermore, COPD management is tailored to disease severity and phenotype, with inhaler technique and adherence being critical determinants of outcomes (Yawn et al., 2012). Introducing unproven therapies like LDN could distract from optimizing established treatments.
Given the lack of guideline endorsement and clinical trial evidence, clinicians should be cautious about adopting LDN for COPD outside of formal research protocols.
How this may change practice
At present, LDN should not alter routine COPD management in primary care. Clinicians should continue to focus on evidence-based interventions including smoking cessation support, inhaler optimization, vaccination, and pulmonary rehabilitation (Yawn et al., 2021).
However, the hypothesis-generating potential of LDN’s immunomodulatory properties may prompt future clinical trials. Should rigorous studies demonstrate safety and efficacy, LDN could emerge as a novel adjunctive therapy, particularly for patients with refractory symptoms or frequent exacerbations.
Primary care providers should remain informed about emerging COPD therapies but prioritize established, guideline-recommended treatments until new evidence justifies practice change.